# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-210292
Filing Date
2026-05-07
Accepted
2026-05-07 07:04:48
Documents
60
Period of Report
2026-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | amlx-20260331.htm iXBRL | 10-Q | 2214715
2 | EX-31.1 | amlx-ex31_1.htm | EX-31.1 | 17601
3 | EX-31.2 | amlx-ex31_2.htm | EX-31.2 | 17593
4 | EX-31.3 | amlx-ex31_3.htm | EX-31.3 | 17593
5 | EX-32.1 | amlx-ex32_1.htm | EX-32.1 | 9751
6 | EX-32.2 | amlx-ex32_2.htm | EX-32.2 | 9749
7 | EX-32.3 | amlx-ex32_3.htm | EX-32.3 | 9748
| Complete submission text file | 0001193125-26-210292.txt |  | 6955770

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | amlx-20260331.xsd | EX-101.SCH | 880703
64 | EXTRACTED XBRL INSTANCE DOCUMENT | amlx-20260331_htm.xml | XML | 946530

Mailing Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 6W CAMBRIDGE MA 02142 617-682-0917
Amylyx Pharmaceuticals, Inc. (Filer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41199 | Film No.: 26950795
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)